Sanofi Stock Creeps Higher On 'Essentially In Line' Guidance For 2026 | Investor's Business DailyBREAKING: [Rare Earths Stocks Skid On Policy Shift]---Sanofi (SNY) stock edged higher early Thursday after the French pharma giant reported adjusted earnings of 91 cents per share on $13.5 billion in fourth-quarter sales. Analysts polled by FactSet expected Sanofi to earn 84 cents a share and report $13.57 billion in sales. During the year-ago period, Sanofi earned 68 cents per share on $11.89 billion in sales. ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

In its upcoming report, Amgen (AMGN) is predicted by Wall Street analysts to post quarterly earnings of $4.74 per share, reflecting a decline of 10.7% compared to the same period last year. Revenues are forecasted to be $9.46 billion, representing a year-over-year increase of 4.2%.The current level reflects an upward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projectio ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is expected to release its quarterly earnings with an estimated EPS of $10.56 and revenue of approximately $3.78 billion.The company's stock has seen a significant increase of over 16%, with a current P/E ratio of approximately 17.Regeneron's financial stability is highlighted by a low debt-to-equity ratio of 0.087 and a strong current ratio of 4.06.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company known for its innovative medicine ...

Key Takeaways AMGN is set to report Q4 results on Feb. 3, with consensus calling for sales of $9.46B and EPS of $4.74.Amgen's newer drugs and biosimilars may lift sales, but Prolia and Xgeva face erosion after U.S. LOE.AMGN's prior-quarter one-time benefits won't be repeated, and higher R&D costs could weigh on margins.Amgen (AMGN) will report fourth-quarter and full-year 2025 results on Feb. 3 after market close. In the last reported quarter, the company's earnings beat expectations by 12.8%. The Zacks Con ...

In this article, we will take a look at the 15 Best S&P 500 Dividend Stocks to Buy in 2026. Dividend stocks have often provided stability when markets get difficult. Dan Lefkovitz, strategist for Morningstar Indexes, said leaning only on dividend payers tends to pull portfolios toward older, more traditional parts of the market.He said adding companies that actively buy back their shares creates a mix that looks much closer to the broader market. Lefkovitz pointed to data showing that an index combining div ...

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - The newsletter is led by a biotech consultant with over 5 years of experience, who has compiled detailed reports on more than 1,000 companies [1] - The investing group, Haggerston BioHealth, caters to both novice and experienced investors, providing insights on product sales, forecasts for major pharmaceutical companies, and various financial analyses [1]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

Core Viewpoint - Amgen Inc. is facing a potential increase in stock price according to Bernstein's target, but legal challenges may impact its performance and reputation [1][4][5]. Group 1: Stock Performance - Bernstein has set a price target of $335 for Amgen, suggesting a potential increase of about 1.38% from the current stock price of $330.06 [1][6]. - The stock has fluctuated today, with a low of $321.71 and a high of $330.83, reflecting its volatility [2]. - Over the past year, Amgen's stock has reached a high of $346.38 and a low of $261.43, indicating significant market fluctuations [2][6]. Group 2: Market Capitalization and Trading Activity - Amgen's market capitalization is approximately $177.73 billion, underscoring its substantial presence in the pharmaceutical industry [3]. - The trading volume for the day is 971,158 shares on the NASDAQ exchange, indicating active investor interest [3]. Group 3: Legal Challenges - Amgen is facing a lawsuit from Sagebrush Health Services, alleging unlawful termination of discounted drug sales, which could affect over 10,000 patients in Nevada [4]. - This legal issue may impact Amgen's reputation and financial performance, necessitating close monitoring by investors [5][6].

LAS VEGAS--(BUSINESS WIRE)--Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush's clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, temporarily prevented it from supplying its clinics with necessary medications from Amgen and other manufacturers. Guru Ch ...